Neuroimmunology Laboratory, Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, G12 8TA, UK.
Vet Extra Neurology, Broadleys Veterinary Hospital, Stirling, FK7 7LE, UK.
J Small Anim Pract. 2022 Feb;63(2):104-112. doi: 10.1111/jsap.13439. Epub 2021 Nov 17.
A previous single-country pilot study indicated serum anti-GM2 and anti-GA1 anti-glycolipid antibodies as potential biomarkers for acute canine polyradiculoneuritis. This study aims to validate these findings in a large geographically heterogenous cohort.
Sera from 175 dogs clinically diagnosed with acute canine polyradiculoneuritis, 112 dogs with other peripheral nerve, cranial nerve or neuromuscular disorders and 226 neurologically normal dogs were screened for anti-glycolipid antibodies against 11 common glycolipid targets to determine the immunoglobulin G anti-glycolipid antibodies with the highest combined sensitivity and specificity for acute canine polyradiculoneuritis.
Anti-GM2 anti-glycolipid antibodies reached the highest combined sensitivity and specificity (sensitivity: 65.1%, 95% confidence interval 57.6 to 72.2%; specificity: 90.2%, 95% confidence interval 83.1 to 95.0%), followed by anti-GalNAc-GD1a anti-glycolipid antibodies (sensitivity: 61.7%, 95% confidence interval 54.1 to 68.9%; specificity: 89.3%, 95% confidence interval 82.0 to 94.3%) and these anti-glycolipid antibodies were frequently present concomitantly. Anti-GA1 anti-glycolipid antibodies were detected in both acute canine polyradiculoneuritis and control animals. Both for anti-GM2 and anti-GalNAc-GD1a anti-glycolipid antibodies, sex was found a significantly associated factor with a female to male odds ratio of 2.55 (1.27 to 5.31) and 3.00 (1.22 to 7.89), respectively. Anti-GalNAc-GD1a anti-glycolipid antibodies were more commonly observed in dogs unable to walk (OR 4.56, 1.56 to 14.87).
Anti-GM2 and anti-GalNAc-GD1a immunoglobulin G anti-glycolipid antibodies represent serum biomarkers for acute canine polyradiculoneuritis.
先前的单国试点研究表明，血清抗-GM2 和抗-GA1 神经节苷脂抗体可能是犬急性多发性神经根神经炎的潜在生物标志物。本研究旨在在一个大的地理异质队列中验证这些发现。
对 175 例临床诊断为犬急性多发性神经根神经炎、112 例其他周围神经、颅神经或神经肌肉疾病和 226 例神经正常的犬的血清进行筛查，以确定针对 11 种常见神经节苷脂靶标检测的免疫球蛋白 G 抗神经节苷脂抗体，用于确定对犬急性多发性神经根神经炎具有最高联合敏感性和特异性的神经节苷脂抗体。
抗-GM2 神经节苷脂抗体达到了最高的联合敏感性和特异性（敏感性：65.1%，95%置信区间 57.6%至 72.2%；特异性：90.2%，95%置信区间 83.1%至 95.0%），其次是抗-GalNAc-GD1a 神经节苷脂抗体（敏感性：61.7%，95%置信区间 54.1%至 68.9%；特异性：89.3%，95%置信区间 82.0%至 94.3%），这些神经节苷脂抗体通常同时存在。抗-GA1 神经节苷脂抗体在犬急性多发性神经根神经炎和对照动物中均有检测到。对于抗-GM2 和抗-GalNAc-GD1a 神经节苷脂抗体，性别均为显著相关因素，女性与男性的比值比分别为 2.55（1.27 至 5.31）和 3.00（1.22 至 7.89）。抗-GalNAc-GD1a 神经节苷脂抗体在无法行走的犬中更为常见（比值比 4.56，1.56 至 14.87）。
抗-GM2 和抗-GalNAc-GD1a 免疫球蛋白 G 神经节苷脂抗体是犬急性多发性神经根神经炎的血清生物标志物。
